RECELL WOUND CARE, page-23

First 23 Last

Share
Profile

Follow
Melody432

1,221 Posts.

464

09/10/24

13:33

Post #: 76044708
Share
Originally posted by ThaLuvDocta: ↑

If Avita Medical (RCEL) does achieve profitability by the third quarter of next year, it could have significant positive implications for its stock performance and financial ratios. Here's how I see this playing out, considering the current trends and financial metrics:
1. Improvement in Investor Sentiment
Profitability would be a key milestone that could shift investor sentiment dramatically. Currently, Avita’s valuation ratios, such as its Price-to-Sales (PS) ratio, remain high, reflecting expectations for future growth but also concerns about sustained losses. If Avita turns a profit, those concerns would ease, potentially leading to an upward revision of price targets from analysts, as it would validate the company's growth strategy and its commercial execution(
Tickergate
)(
Stock Analysis
).
2. Reduction in Negative Profitability Metrics
Avita's return on equity (ROE) and return on assets (ROA) are currently very negative, reflecting poor capital efficiency due to losses. If profitability is reached, both ROE and ROA should improve significantly, as the company starts generating positive net income. This would also likely lead to an improvement in investor confidence, making the stock more attractive to both institutional and retail investors(
Stock Analysis
).
3. Debt Management
The debt-to-equity ratio (currently at 1.35) has increased in recent years, indicating that Avita has been relying on debt to fund operations while being unprofitable. Once profitability is achieved, Avita could begin to reduce its debt load, thereby improving this ratio. A lower debt burden would enhance financial flexibility and reduce interest expenses, further supporting long-term profitability(
Stock Analysis
).
4. Valuation Adjustment
With profitability, Avita’s enterprise value (EV) to EBITDA ratio could move from its current negative range into positive territory, which would likely lead to a re-rating of the stock. Investors typically value companies with predictable earnings at a premium, especially in the medical device sector. As Avita moves from a growth story to a profitable entity, its valuation could reflect more favorable multiples(
Fintel - Financial Intelligence
)(
Stock Analysis
).
5. Stock Price Implications
If the profitability target is met, and Avita’s growth continues as expected (with revenue projected to increase by over 40% in 2025), the stock could reach or exceed the higher end of analyst price targets. Given that the current average target is around $15 with a potential upside to $23(
Stock Analysis
)(
Fintel - Financial Intelligence
), profitability could drive the stock toward these upper bounds. Additionally, if broader market conditions remain favorable, reaching $18-$21 within a year is plausible, as analysts like those from Cantor Fitzgerald have predicted(
Tickergate
).
Risks:
Despite these potential upsides, profitability could be delayed if Avita faces unexpected challenges in scaling operations or if broader economic conditions worsen. Also, being a smaller, high-growth company, Avita is still susceptible to volatility, especially as it continues to operate in the high-risk medical device space(
Stock Analysis
).
In summary, if Avita achieves its profitability goal, I anticipate a positive revaluation of the stock, improvement in financial ratios, and potential stock price appreciation towards the $18-$21 range.

Expand

It's that "if" word that sometimes worries me.
AVH Price at posting: $3.01 Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce progresses testing of gel to treat bacterial skin infections

AHK

Ark Mines provides strategic update following mining lease submission

STK

Rogozna grows with gold equivalent grading 1.1g/t across 545.7m for Strickland

TTT

Titomic jumps +6% as it incorporates Microsoft Hololens tech

LU7

The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour

There are more pages in this discussion • 4 more messages in this thread...

First 23 Last

Add AVH (ASX) to my watchlist

(20min delay)
Last $3.02		Change -0.080(2.58%)		Mkt cap ! $212.9M

Open	High	Low	Value	Volume
$3.09	$3.11	$3.00	$438.3K	144.3K

Buyers (Bids)

No.	Vol.	Price($)
1	3373	$3.02

Sellers (Offers)

Price($)	Vol.	No.
$3.04	69	1

View Market Depth

No.	Vol.	Price($)
1	3373	3.020
1	502	3.010
6	11562	3.000
1	49	2.990
1	49	2.980

Price($)	Vol.	No.
3.040	69	1
3.050	9867	2
3.060	4369	2
3.110	10000	1
3.160	2553	3

Last trade - 16.10pm 09/10/2024 (20 minute delay)

AVH (ASX) Chart

RECELL WOUND CARE, page-23

Recce progresses testing of gel to treat bacterial skin infections

Ark Mines provides strategic update following mining lease submission

Rogozna grows with gold equivalent grading 1.1g/t across 545.7m for Strickland

Titomic jumps +6% as it incorporates Microsoft Hololens tech

The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

RECELL WOUND CARE, page-23

Top Stories

Recce progresses testing of gel to treat bacterial skin infections

Ark Mines provides strategic update following mining lease submission

Rogozna grows with gold equivalent grading 1.1g/t across 545.7m for Strickland

Titomic jumps +6% as it incorporates Microsoft Hololens tech

The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News